Table 2.

The characteristics of the four included trials.

Study	EINSTEIN 14	SELECT-D 15	XALIA 19	Yang 20
Rivaroxaban	15 mg twice daily for 21 days, followed by 20 mg once daily	15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months	rivaroxaban alone or after heparin or fondaparinux for ≤48 h	10 mg twice daily for 30 days, then adjusted for 60 days
Control	enoxaparin 1·0 mg/kg twice daily and warfarin or acenocoumarol; international normalized ratio 2·0–3·0	dalteparin 200 IU/kg daily during month 1, then 150 IU/kg daily for months 2–6	early switchers (rivaroxaban after heparin or fondaparinux for >48 h to 14 days and/or a VKA for 1–14 days); standard anticoagulation (heparin or fondaparinux and a VKA); LMWH alone; and miscellaneous (other heparins, fondaparinux alone, VKA alone).	LMWH 0.4 ml twice daily for 30 days, then adjusted dose for 60 days